Cargando…

Case report: Intensive statin and PCSK-9 inhibitor combo reduces plaque volume and stenosis in ischemic stroke patient

Intracranial atherosclerotic ischemic stroke dramatically impacts the quality of life among the elderly. Statins therapy has been proven to be effective in plaque stabilization and alleviation in patients with intracranial atherosclerotic ischemic stroke. According to recent studies, these effects m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zeng, Weiqi, Shi, Yunfei, Fan, Meng, Shi, Changzheng, Tan, Zefeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10382625/ https://www.ncbi.nlm.nih.gov/pubmed/37520968 http://dx.doi.org/10.1016/j.heliyon.2023.e18397

Ejemplares similares

Association of PCSK9 levels and genetic polymorphisms with stroke recurrence and functional outcome after acute ischemic stroke
por: Chen, Weiqi, et al.
Publicado: (2022)

Pharmacological Strategies beyond Statins: Ezetimibe and PCSK9 Inhibitors
por: Choi, Jah Yeon, et al.
Publicado: (2019)

Association of PCSK9 Inhibitor Initiation on Statin Adherence and Discontinuation
por: LaFratte, Christopher, et al.
Publicado: (2023)

Effect of PCSK9 inhibition in combination with statin therapy on intracranial atherosclerotic stenosis: A high-resolution MRI study
por: Wu, Lingshan, et al.
Publicado: (2023)

Plasma PCSK9 levels are significantly modified by statins and fibrates in humans
por: Mayne, Janice, et al.
Publicado: (2008)

Metabolomic Consequences of Genetic Inhibition of PCSK9 Compared With Statin Treatment
por: Sliz, Eeva, et al.
Publicado: (2018)

Statins and PCSK9 inhibitors: What is their role in coronavirus disease 2019?
por: Barkas, Fotios, et al.
Publicado: (2021)

Effect of statin on progression of symptomatic basilar artery stenosis and subsequent ischemic stroke
por: Yum, Kyu Sun, et al.
Publicado: (2017)

Recent Advances on the Roles of PCSK-9 Inhibitors in the Management of Acute Ischemic Stroke Patients
por: Ilut, Silvina, et al.
Publicado: (2022)

Combo Prospecting
por: Hughes, Tony
Publicado: (2018)

Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials
por: Colhoun, Helen M, et al.
Publicado: (2014)

Circulating Mature PCSK9 Level Predicts Diminished Response to Statin Therapy
por: Kuyama, Naoto, et al.
Publicado: (2021)

Correlation of PCSK9 Gene Polymorphism with Cerebral Ischemic Stroke in Xinjiang Han and Uygur Populations
por: Han, Dengfeng, et al.
Publicado: (2014)

PCSK9 and Calcific Aortic Valve Stenosis: Moving Beyond Lipids
por: Leopold, Jane A.
Publicado: (2020)

Genetic and In Vitro Inhibition of PCSK9 and Calcific Aortic Valve Stenosis
por: Perrot, Nicolas, et al.
Publicado: (2020)

Independent association of PCSK9 with platelet reactivity in subjects without statin or antiplatelet agents
por: Wang, Shuai, et al.
Publicado: (2022)

The Effects of Statins, Ezetimibe, PCSK9-Inhibitors, Inclisiran, and Icosapent Ethyl on Platelet Function
por: Di Costanzo, Assunta, et al.
Publicado: (2023)

Relationship Between Carotid Stenosis and Infarct Volume in Ischemic Stroke Patients
por: Alagöz, Aybala Neslihan, et al.
Publicado: (2016)

Real world effectiveness of PCSK-9 inhibitors combined with statins versus statins-based therapy among patients with very high risk of atherosclerotic cardiovascular disease in China (RWE-PCSK study)
por: LIU, Yu-Qi, et al.
Publicado: (2021)

May statins and PCSK9 inhibitors be protective from COVID-19 in familial hypercholesterolemia subjects?
por: Scicali, Roberto, et al.
Publicado: (2020)

Statin-Induced Geranylgeranyl Pyrophosphate Depletion Promotes PCSK9–Dependent Adipose Insulin Resistance
por: Shu, Xin, et al.
Publicado: (2022)

Hypocholesterolaemic treatment in coronary unit: from statins to anti PCSK9 therapies and bempedoic acid
por: Ferri, Nicola, et al.
Publicado: (2023)

The Many Roles of Statins in Ischemic Stroke
por: Zhao, Jingru, et al.
Publicado: (2014)

The Influence of OLR1 and PCSK9 Gene Polymorphisms on Ischemic Stroke: Evidence from a Meta-Analysis
por: Au, Anthony, et al.
Publicado: (2015)

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in aortic stenosis - Is this the light at the end of the tunnel for patients with aortic stenosis?
por: Agstam, Sourabh, et al.
Publicado: (2021)

The annual rate of coronary artery calcification with combination therapy with a PCSK9 inhibitor and a statin is lower than that with statin monotherapy
por: Ikegami, Yuichi, et al.
Publicado: (2018)

PCSK9 inhibitors: Add-on therapy to reduce stroke risk
por: Earl, Grace
Publicado: (2019)

Relationship of thyroid function with intracranial arterial stenosis and carotid atheromatous plaques in ischemic stroke patients with euthyroidism
por: Liu, Junfeng, et al.
Publicado: (2017)

The Effect of PCSK9 Inhibition on the Stabilization of Atherosclerotic Plaque Determined by Biochemical and Diagnostic Imaging Methods
por: Basiak, Marcin, et al.
Publicado: (2023)

Can metformin stabilize PCSK9 level in stable coronary artery disease patients treated with statins?
por: Shek, Aleksandr B., et al.
Publicado: (2019)

PCSK9 Levels and Metabolic Profiles in Elderly Subjects with Different Glucose Tolerance under Statin Therapy
por: Mäkelä, Kari A., et al.
Publicado: (2021)

The Effect of Intensive Statin Therapy on Symptomatic Intracranial Arterial Stenosis
por: ZHOU, Peiyang, et al.
Publicado: (2018)

The Effects of Statin and Niacin on Plaque Stability, Plaque Regression, Inflammation and Oxidative Stress in Patients With Mild to Moderate Coronary Artery Stenosis
por: Lee, Kyounghoon, et al.
Publicado: (2011)

Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism
por: Chan, Dick C., et al.
Publicado: (2018)

Coronary Artery Plaque Regression by a PCSK9 Antibody and Rosuvastatin in Double-heterozygous Familial Hypercholesterolemia with an LDL Receptor Mutation and a PCSK9 V4I Mutation
por: Shirahama, Ryo, et al.
Publicado: (2018)

Characteristics of culprit intracranial plaque without substantial stenosis in ischemic stroke using three-dimensional high-resolution vessel wall magnetic resonance imaging
por: Tian, Xia, et al.
Publicado: (2023)

Investigation of highly expressed PCSK9 in atherosclerotic plaques and ox-LDL-induced endothelial cell apoptosis
por: Li, Jiao, et al.
Publicado: (2017)

FOURIER & PCSK9 RNAi: Towards enhancing durability and efficacy of PCSK9 inhibitors
por: Hassan, Mohamed
Publicado: (2017)

The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol
por: Seidah, Nabil G.
Publicado: (2017)

PCSK9 Inhibitors in a Statin-Intolerant Transgender Man With Heterozygous Familial Hypercholesterolemia: A Case Report
por: Pirazzi, Carlo, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_tvgp24u7ltklgrdmi1vnmgnmkl